癌症的學名藥市場分析 是由出版商RNCOS E-Services Pvt. Ltd.在2011年09月所出版的。
這份英文市場調查報告書包含80 Pages 價格從美金1000起跳。
全球癌症的非專利處方藥市場預計從2010∼2014年將以年複合成長率27%擴大。由於暢銷的抗癌劑將在今後數年專利失效，同時也為了削減高漲的藥費而廣泛轉用學名藥，這些因素都推動著市場的成長。一般認為美國到2011年已花費100億美金在專利抗癌藥物上了。
本報告提供全球癌症學名藥市場相關整體分析，彙整市場現狀和產業發展，競爭環境，以及產品開發平台趨勢，產品的技術創新趨勢等資料，為您概述為以下內容。
第1章 分析師的觀點
第2章 調查方法
第3章 癌症治療藥市場
第4章 推動市場因素和阻礙因素
- 癌症發生率的上升
- 癌症治療藥:關注領域
- 合作的增加
- 追求新學名藥的企業
第5章 癌症的學名藥:市場概要
第6章 口服學名藥
- Arimidex (Anastrozole)
- Casodex (Bicalutamide)
- Aromasin (Exemestane)
- Femara (Letrozole)
- Leucovorin Calcium
- Megestrol Acetate
- Mercaptopurine
- Tarceva (Erlotinib)
- Tamoxifen
- Methotrexate
- Flutamide
- Hydrea (Hydroxyurea)
第7章 注射學名藥
- Eligard (Leuprolide Acetate)
- Zoladex (Goserelin)
- Camptosar (Irinotecan)
- Zoledronic Acid
- Velcade (Bortezomib)
- Kytril (Granisetron)
- Taxotere (Docetaxel)
- Gemzar (Gemcitabine)
第8章 開發平台藥物
第9章 主要企業
- Teva
- Hospira
- Ranbaxy
- Cipla
- Natco Pharma
- Dr. Reddy's
圖表
Abstract
Cancer has emerged as one of the major causes of death globally and has made
the pharmaceutical & biotech companies proactive to foray research &
development to develop new therapies for its treatment. With increasing cancer
incidences and competition in the healthcare industry around the world, the
cancer market represents a lucrative sector for the generic players around the
world due to the fact that price erosion is significantly lower than the other
segments.
According to our new research report, “Cancer Generics Market
Analysis”, the global cancer generics market is anticipated to grow at a
CAGR of around 27% during 2010-2014. Market growth will be driven by upcoming
anti-cancer blockbuster drugs patent expirations and the rising drugs bill
that will encourage payers to address the barriers to generics access in order
to control costs. As per our research, oncology drugs worth around US$10
Billion are expected to lose patent rights in the US by 2011. As the
governments and private players have stepped in the industry across various
geographical locations, the future prospects of the market shows immense
opportunities to tap on.
Our thorough study on the industry indicates that the Global Cancer generics
drugs industry has witnessed a number of product launches and mergers &
acquisitions in the past few years. The main focus of the companies has been
to introduce effective and quality products in the market so that it gains a
worldwide acceptance. With new markets and new products for generics
manufacturers within the cancer market, it is anticipated that a harsh
environment for companies focusing on novel cancer treatments is about to
come. However, within the cancer market, there remains a high level of unmet
need, and novel products demonstrating improved clinical attributes to any
degree that would be expected to capture the market share from older generic
drugs.
On the competitive front, Teva & Hospira are presently the global market
leader in cancer generics drugs market. Meanwhile, some Indian companies are
also using their experiences within the deregulated markets to produce
dossiers and products suited for the regulated markets.
The report provides extensive information and rational analysis of the global
cancer generics drugs market. It has thoroughly examined current market
drivers, industrial developments, and competitive landscapes to enable clients
understand the market structure and its progress in the coming years. The
report also provides an insight into different marketed products along with
pipeline analysis to present an overview of the developments taking place in
the global cancer generics drugs industry. Further, a review of product
innovations and recent industry activity has also been covered in the report.
Table of Contents
1. Analyst View
2. Research Methodology
3. Cancer Therapeutics Market
4. Market Drivers & Trends
- 4.1. Higher Incidences of Cancer
- 4.2. Oncology Therapeutics: Major Focus Area
- 4.3. Alliances on the Rise
- 4.4. Companies Thriving for New Generic Cancer Drugs
5. Generic Cancer Drugs: Market Overview
6. Oral Generic Cancer Drugs
- 6.1. Arimidex (Anastrozole)
- 6.2. Casodex (Bicalutamide)
- 6.3. Aromasin (Exemestane)
- 6.4. Femara (Letrozole)
- 6.5. Leucovorin Calcium
- 6.6. Megestrol Acetate
- 6.7. Mercaptopurine
- 6.8. Tarceva (Erlotinib)
- 6.9. Tamoxifen
- 6.10. Methotrexate
- 6.11. Flutamide
- 6.12. Hydrea (Hydroxyurea)
7. Generic Cancer Injectables
- 7.1. Eligard (Leuprolide Acetate)
- 7.2. Zoladex (Goserelin)
- 7.3. Camptosar (Irinotecan)
- 7.4. Zoledronic Acid
- 7.5. Velcade (Bortezomib)
- 7.6. Kytril (Granisetron)
- 7.7. Taxotere (Docetaxel)
- 7.8. Gemzar (Gemcitabine)
8. Pipeline Drugs
9. Key Players
- 9.1. Teva
- 9.2. Hospira
- 9.3. Ranbaxy
- 9.4. Cipla
- 9.5. Natco Pharma
- 9.6. Dr. Reddy' s
List of Figures:
- Figure 4-1: Global - Cancer Deaths (Million), 2008 & 2030
- Figure 4-2: Global - Estimated Number of New Cancer Cases by World Area
(2008)
- Figure 5-1: Global - Cancer Generics Market (Billion US$), 2010 & 2014
List of Tables:
- Table 6-1: List of Online Pharmacy Chains Selling Generic Arimidex
- Table 6-2: Cost Comparison of Generic & Branded Arimidex
- Table 6-3: List of Online Pharmacy Chains Selling Generic Bicalutamide
- Table 6-4: Cost Comparison of Generic & Branded Casodex
- Table 6-5: List of Online Pharmacy Chains Selling Generic Exemestane
- Table 6-6: Cost Comparison of Generic & Branded Exemestane
- Table 6-7: List of Online Pharmacy Chains Selling Generic Letrozole
- Table 6-8: Cost Comparison of Generic & Branded Letrozole
- Table 6-9: List of Online Pharmacy Chains Selling Generic Leucovorin
Calcium
- Table 6-10: Cost Comparison of Generic & Branded Leucovorin Calcium
- Table 6-11: List of Online Pharmacy Chains Selling Generic Megestrol
Acetate
- Table 6-12: Cost of Generic Megestrol Acetate
- Table 6-13: List of Online Pharmacy Chains Selling Generic Mercaptopurine
- Table 6-14: Cost Comparison of Generic & Branded Mercaptopurine
- Table 6-15: Cost Comparison of Generic & Branded Erlotinib
- Table 6-16: List of Online Pharmacy Chains Selling Generic Tamoxifen
- Table 6-17: Cost Comparison of Generic & Branded Tamoxifen
- Table 6-18: List of Online Pharmacy Chains Selling Generic Methotrexate
- Table 6-19: Cost of Generic Methotrexate
- Table 6-20: List of Online Pharmacy Chains Selling Generic Flutamide
- Table 6-21: Cost Comparison of Generic & Branded Flutamide
- Table 6-22: List of Online Pharmacy Chains Selling Generic Hydroxyurea
- Table 6-23 Cost Comparison of Generic & Branded Hydroxyurea
- Table 7-1: Cost Comparison of Generic & Branded Leuprolide Acetate
Injection
- Table 7-2: Cost Comparison of Generic & Branded Camptosar Injection
- Table 7-3: Cost Comparison of Generic & Branded Zometa Injection
- Table 7-4: Cost Comparison of Generic & Branded Velcade Injection
- Table 7-5: Cost Comparison of Generic & Branded Docetaxel Injection
- Table 7-6: Cost Comparison of Generic & Branded Gemzar Injection
- Table 8-1: List of Key Pipeline Generic Cancer Drugs by Phases & Area of
Study
